Eisai to Unveil New Real-World Lecanemab Data at AAIC 2026

The conference, scheduled for July 12–15, will serve as the platform for the LEADER study, a comprehensive retrospective analysis evaluating lecanemab’s performance across diverse clinical settings in the United States three years after its initial approval. Presentations will provide the first reported findings on at-home subcutaneous administration and insights into maintenance dosing regimens utilizing intravenous treatment every four weeks.

Beyond the primary LEADER data, the program includes a deep dive into the subcutaneous formulation of the drug, covering both emerging clinical trial results and practical considerations for patient use. The research agenda also extends to the AHEAD 3-45 study, which focuses on preclinical Alzheimer’s disease, with updates expected on participant engagement and trial retention strategies. The symposium will also address broader therapeutic challenges, including the management of amyloid-related imaging abnormalities and the impact of biomarkers on cognitive performance across different patient demographics.